Dr. Reddy’s Laboratories has informed that Dr. Reddy’s Laboratories SA, a wholly-owned subsidiary of the company (‘Dr. Reddy’s’) has entered into a strategic collaboration and exclusive Licensing agreement with Immutep SAS, a wholly-owned subsidiary of Immutep (ASX: IMM; NASDAQ: IMMP) (‘Immutep’) to develop and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. The details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed. A press release to be issued in relation to the above matter is enclosed.
The above information is a part of company’s filings submitted to BSE.
